Little House Capital LLC Makes New Investment in ResMed Inc. $RMD

Little House Capital LLC purchased a new position in shares of ResMed Inc. (NYSE:RMD) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 3,096 shares of the medical equipment provider’s stock, valued at approximately $695,000.

Several other large investors have also made changes to their positions in the company. Imprint Wealth LLC bought a new stake in shares of ResMed during the 3rd quarter worth $26,000. WFA of San Diego LLC bought a new position in ResMed in the second quarter valued at about $26,000. International Assets Investment Management LLC bought a new position in ResMed in the fourth quarter valued at about $25,000. ORG Partners LLC raised its stake in ResMed by 181.6% during the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 69 shares in the last quarter. Finally, Sunbelt Securities Inc. bought a new position in shares of ResMed in the third quarter worth about $31,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on RMD. Royal Bank Of Canada downgraded shares of ResMed from an “outperform” rating to a “sector perform” rating and set a $234.00 price target on the stock. in a research note on Thursday. Wells Fargo & Company dropped their price objective on shares of ResMed from $227.00 to $225.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 8th. Mizuho cut their target price on shares of ResMed from $235.00 to $220.00 and set an “outperform” rating on the stock in a research report on Wednesday. Jefferies Financial Group decreased their target price on shares of ResMed from $240.00 to $225.00 and set a “hold” rating on the stock in a research note on Friday, July 10th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $230.00 price target (down from $286.00) on shares of ResMed in a report on Wednesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, ResMed has a consensus rating of “Moderate Buy” and an average price target of $250.00.

Insider Transactions at ResMed

In other news, CEO Michael J. Farrell sold 4,991 shares of the firm’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $218.55, for a total transaction of $1,090,783.05. Following the completion of the transaction, the chief executive officer owned 466,223 shares of the company’s stock, valued at approximately $101,893,036.65. This trade represents a 1.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 14,973 shares of company stock valued at $3,096,067. Corporate insiders own 0.65% of the company’s stock.

ResMed Stock Performance

NYSE:RMD opened at $198.86 on Friday. The stock has a market cap of $28.85 billion, a P/E ratio of 19.18, a price-to-earnings-growth ratio of 1.19 and a beta of 0.78. The company has a current ratio of 3.01, a quick ratio of 2.33 and a debt-to-equity ratio of 0.06. The stock’s 50-day moving average is $199.40 and its 200-day moving average is $226.64. ResMed Inc. has a 1-year low of $180.26 and a 1-year high of $293.81.

ResMed (NYSE:RMD) last issued its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.07. ResMed had a net margin of 27.44% and a return on equity of 25.35%. The business had revenue of $1.43 billion during the quarter, compared to analyst estimates of $1.42 billion. During the same quarter last year, the business earned $2.37 EPS. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. Equities research analysts anticipate that ResMed Inc. will post 11.13 earnings per share for the current year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Thursday, May 14th were given a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 1.2%. The ex-dividend date was Thursday, May 14th. ResMed’s dividend payout ratio is 23.14%.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.